Galera Therapeutics Analyst Ratings
Galera Therapeutics Analyst Ratings
While ratings are subjective and will change, the latest Galera Therapeutics (GRTX) rating was a reiterated with a price target of $0.00 to $6.00. The current price Galera Therapeutics (GRTX) is trading at is $2.75, which is within the analyst's predicted range.| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 07/17/2023 | 118.18% | HC Wainwright & Co. | → $6 | Reiterates | Buy → Buy |
| 03/22/2023 | 118.18% | HC Wainwright & Co. | $10 → $6 | Maintains | Buy |
| 02/21/2023 | 118.18% | Piper Sandler | → $6 | Initiates Coverage On | → Overweight |
| 02/16/2023 | 154.55% | B of A Securities | $2 → $7 | Upgrades | Underperform → Buy |
| 02/16/2023 | 263.64% | HC Wainwright & Co. | → $10 | Reiterates | → Buy |
| 05/27/2022 | -27.27% | B of A Securities | → $2 | Downgrades | Neutral → Underperform |
| 12/20/2021 | 627.27% | Citigroup | $11 → $20 | Maintains | Buy |
| 12/15/2021 | 263.64% | HC Wainwright & Co. | → $10 | Upgrades | Neutral → Buy |
| 12/15/2021 | 445.45% | BTIG | → $15 | Upgrades | Neutral → Buy |
| 10/20/2021 | — | HC Wainwright & Co. | Downgrades | Buy → Neutral | |
| 10/19/2021 | — | BTIG | Downgrades | Buy → Neutral | |
| 12/16/2020 | 445.45% | Credit Suisse | $9 → $15 | Upgrades | Neutral → Outperform |
| 12/07/2020 | 445.45% | HC Wainwright & Co. | → $15 | Initiates Coverage On | → Buy |
| 11/11/2020 | 227.27% | Credit Suisse | $8 → $9 | Maintains | Neutral |
| 07/29/2020 | 190.91% | Credit Suisse | $14 → $8 | Maintains | Neutral |
| 12/02/2019 | 990.91% | BTIG | → $30 | Initiates Coverage On | → Buy |
| 12/02/2019 | 445.45% | B of A Securities | → $15 | Initiates Coverage On | → Buy |
| 12/02/2019 | 627.27% | Citigroup | → $20 | Initiates Coverage On | → Buy |
| 12/02/2019 | 409.09% | Credit Suisse | → $14 | Initiates Coverage On | → Neutral |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 07/17/2023 | 118.18% | HC Wainwright公司 | →$6 | 重申 | 購買→購買 |
| 03/22/2023 | 118.18% | HC Wainwright公司 | $10→$6 | 維護 | 買 |
| 02/21/2023 | 118.18% | 派珀·桑德勒 | →$6 | 開始承保 | →超重 |
| 02/16/2023 | 154.55% | B of A證券 | $2→$7 | 升級 | 表現不佳的→收購 |
| 02/16/2023 | 263.64% | HC Wainwright公司 | →$10 | 重申 | →購買 |
| 2022年05月27日 | -27.27% | B of A證券 | →$2 | 評級下調 | 中性→表現不佳 |
| 12/20/2021 | 627.27% | 花旗集團 | $11→$20 | 維護 | 買 |
| 2021年12月15日 | 263.64% | HC Wainwright公司 | →$10 | 升級 | 中性→購買 |
| 2021年12月15日 | 445.45% | BTIG | →$15 | 升級 | 中性→購買 |
| 10/20/2021 | - | HC Wainwright公司 | 評級下調 | 購買→中性 | |
| 10/19/2021 | - | BTIG | 評級下調 | 購買→中性 | |
| 12/16/2020 | 445.45% | 瑞士信貸 | $9→$15 | 升級 | 中性→表現優異 |
| 12/07/2020 | 445.45% | HC Wainwright公司 | →$15 | 開始承保 | →購買 |
| 11/11/2020 | 227.27% | 瑞士信貸 | $8→$9 | 維護 | 中性 |
| 07/29/2020 | 190.91% | 瑞士信貸 | $14→$8 | 維護 | 中性 |
| 2019年2月12日 | 990.91% | BTIG | →$30 | 開始承保 | →購買 |
| 2019年2月12日 | 445.45% | B of A證券 | →$15 | 開始承保 | →購買 |
| 2019年2月12日 | 627.27% | 花旗集團 | →$20 | 開始承保 | →購買 |
| 2019年2月12日 | 409.09% | 瑞士信貸 | →$14 | 開始承保 | →中性 |
What is the target price for Galera Therapeutics (GRTX)?
Galera治療公司(GRTX)的目標價格是多少？
The latest price target for Galera Therapeutics (NASDAQ: GRTX) was reported by HC Wainwright & Co. on July 17, 2023. The analyst firm set a price target for $6.00 expecting GRTX to rise to within 12 months (a possible 118.18% upside). 5 analyst firms have reported ratings in the last year.
伽萊拉治療公司(納斯達克代碼：GRTX)的最新目標價是由HC Wainwright&Co.於2023年7月17日報道的。這家分析公司將目標價定為6美元，預計GRTX將在12個月內上漲至(可能上漲118.18)。去年有5家分析公司公佈了評級。
What is the most recent analyst rating for Galera Therapeutics (GRTX)?
Galera治療公司(GRTX)的最新分析師評級是多少？
The latest analyst rating for Galera Therapeutics (NASDAQ: GRTX) was provided by HC Wainwright & Co., and Galera Therapeutics reiterated their buy rating.
加萊拉治療公司(納斯達克代碼：GRTX)的最新分析師評級是由HC Wainwright&Co.提供的，加萊拉治療公司重申了他們的買入評級。
When is the next analyst rating going to be posted or updated for Galera Therapeutics (GRTX)?
Galera治療公司(GRTX)的下一次分析師評級將於何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Galera Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Galera Therapeutics was filed on July 17, 2023 so you should expect the next rating to be made available sometime around July 17, 2024.
分析師在進行了廣泛的研究後得出股票評級，其中包括查閱公共財務報表，與Galera治療公司的高管和客戶交談，以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。Galera治療公司的上一次評級是在2023年7月17日提交的，所以你應該預計下一次評級將在2024年7月17日左右的某個時候提供。
Is the Analyst Rating Galera Therapeutics (GRTX) correct?
分析師對Galera Treateutics(GRTX)的評級正確嗎？
While ratings are subjective and will change, the latest Galera Therapeutics (GRTX) rating was a reiterated with a price target of $0.00 to $6.00. The current price Galera Therapeutics (GRTX) is trading at is $2.75, which is within the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但最新的Galera治療公司(GRTX)評級被重申，目標價在0.00美元至6.00美元之間。Galera治療公司(GRTX)目前的交易價格為2.75美元，在分析師的預測範圍內。